Pharmaceuticals Ultrasector Financial Statements From 2010 to 2025
| PHPSX Fund | USD 19.96 0.08 0.40% |
Check Pharmaceuticals Ultrasector financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmaceuticals Ultrasector's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pharmaceuticals financial statements analysis is a perfect complement when working with Pharmaceuticals Ultrasector Valuation or Volatility modules.
Pharmaceuticals |
Pharmaceuticals Ultrasector Profund Mutual Fund Price To Earning Analysis
Pharmaceuticals Ultrasector's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Pharmaceuticals Ultrasector Price To Earning | 5.75 X |
Most of Pharmaceuticals Ultrasector's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmaceuticals Ultrasector Profund is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Pharmaceuticals Ultrasector Price To Earning Component Assessment
Based on the latest financial disclosure, Pharmaceuticals Ultrasector Profund has a Price To Earning of 5.75 times. This is 75.57% lower than that of the ProFunds family and 73.78% lower than that of the Family category. The price to earning for all United States funds is 11.94% higher than that of the company.
Pharmaceuticals Ultrasector Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharmaceuticals Ultrasector's current stock value. Our valuation model uses many indicators to compare Pharmaceuticals Ultrasector value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmaceuticals Ultrasector competition to find correlations between indicators driving Pharmaceuticals Ultrasector's intrinsic value. More Info.Pharmaceuticals Ultrasector Profund is rated top fund in price to earning among similar funds. It also is rated top fund in price to book among similar funds fabricating about 0.48 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Pharmaceuticals Ultrasector Profund is roughly 2.08 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmaceuticals Ultrasector's earnings, one of the primary drivers of an investment's value.About Pharmaceuticals Ultrasector Financial Statements
Pharmaceuticals Ultrasector investors use historical fundamental indicators, such as Pharmaceuticals Ultrasector's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pharmaceuticals Ultrasector. Please read more on our technical analysis and fundamental analysis pages.
The fund invests in financial instruments that the fund Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index represents the pharmaceuticals segment of the SP Total Market Index, which comprises the following sub-industry pharmaceuticals. The fund is non-diversified.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VALE | Vale SA ADR | |
| EGY | Vaalco Energy | |
| CMCSA | Comcast Corp |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |